Expression of Elongation Factor (EF)-Tu Is Correlated with Prognosis of Gastric Adenocarcinomas

Xu, Chaoyang; Wang, Jianjun; Li, Jiajia; Fang, Rengui

doi:10.3390/ijms12106645

Cited by 11 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2015, Seyfried [ 34 ] developed an interesting view on the mitochondrial origin of cancers, on the basis that cancers originate from damage to the mitochondria rather than from damage to the cell genome, and that the genomic damage in tumor cells follows, rather than precedes, the disturbances in cell respiration. Indeed, in the case of TUFM, a direct association between its down-regulation and induction of EMT and carcinogenesis was shown for lung cancer [ 35 ], and its down-regulation as an indicator of an advanced stage of disease was shown for gastric cancer [ 36 ]. On the other side, TUFM overexpression was reported negative prognostic factor for colorectal cancer [ 37 ] and human pancreatic adenocarcinoma [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting

et al. 2018

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common and lethal form of brain tumor. The prognosis for patients remains poor, despite the combination of new preoperative and intraoperative neuroimaging, radical surgery, and recent advances in radiotherapy and chemotherapy. To improve GBM therapy and patient outcome, sustained drug delivery to glioma cells is needed, while minimizing toxicity to adjacent neurons and glia cells. This might be achieved through an anti-proteomic approach based on nanobodies, the single-domain antigen-binding fragments of heavy-chain antibodies of the camelid adaptive immune system. We report here on the validation and quantification of a nanobody raised against mitochondrial translation elongation factor (TUFM). Differential expression of TUFM was examined in different GBM cell lines and GBM tissue at the protein and mRNA levels, as compared to their expression in neural stem cells and normal brain tissue. We further used in-silico modelling and immunocytochemistry to define the specificity of anti-TUFM nanobody (Nb206) towards GBM stem cells, as compared to GBM cell lines (U251MG and U87MG cells). Due to its specificity and pronounced inhibitory effect on GBM stem cell growth, we propose the use of this anti-TUFM nanobody for GBM in vitro immunoimaging and potentially also cancer stem cell targeting.

show abstract

Section: Discussionmentioning

confidence: 99%

Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The final score was determined by the combined staining score. A score (extent + intensity) ≤1 was considered negative, and a score between 2 and 6 was considered positive [ 30 , 31 ]. p53 staining was semiquantitatively assessed in ten representative fields chosen randomly under a microscope with a high-power (×400) objective.…”

Section: Methodsmentioning

confidence: 99%

Expression and clinicopathologic significance of TUFM and p53 for the normal–adenoma–carcinoma sequence in colorectal epithelia

Zhang

et al. 2017

World J Surg Onc

View full text Add to dashboard Cite

BackgroundEvidence indicates that most cases of colorectal carcinoma (CRC) develop from adenoma. A previous study demonstrated that mitochondrial Tu translation elongation factor (TUFM) might serve as an independent prognostic factor for colorectal cancer. However, the expression and function of TUFM in the normal–adenoma–cancer sequence have not been reported. In this study, we investigated the clinicopathologic significance of TUFM and p53 expression for the normal–adenoma–carcinoma sequence in colorectal epithelia and evaluated the roles of TUFM during the progression of colorectal tumors.MethodsParaffin-embedded specimens from 261 colorectal normal mucosa samples, 157 adenomas, and 104 early carcinomas were analyzed for TUFM and p53 expression by immunohistochemistry.ResultsExpression of TUFM and p53 was significantly increased during the colorectal normal–adenoma–carcinoma sequence (all P < 0.05). The expression of TUFM and p53 was associated with histologic type of adenomas (P = 0.028; P = 0.001) and grade of dysplasia (all P = 0.001). Expression of TUFM was positively correlated with that of p53 (r = 0.319, P = 0.001).ConclusionsUpregulated TUFM expression may play an important role in the transformation from colorectal normal mucosa to carcinoma through adenoma. Combined immunohistochemical detection of TUFM and p53 may be useful for evaluating the biological behavior of colorectal adenoma.

show abstract

“…The expression level of EF-Tu in several types of cancers has been investigated and changes in its expression level were specified. Upregulation of both EF-Tu and the cytoplasmic elongation factor EF-1α in PDAC patients has been reported (41).…”

Section: Discussionmentioning

confidence: 99%

Identification of antibody reactive proteins in pancreatic cancer using 2D immunoblotting and mass spectrometry

et al. 2018

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized by early invasiveness and resistance to treatment. Surgery in early stages is the only effective treatment, thus finding new biomarkers for the early detection of PDAC remains a major challenge. The present study aimed to compare the immunoproteome between PDAC patients and healthy controls using serological proteome analysis method. Firstly, cell lysates from two different pancreatic cancer cell lines were separated by two dimensional (2D) gels, and then transferred onto membranes probed with sera from 20 PDAC patients and 10 healthy controls. Proteins differentially reacting with autoantibodies in PDAC patients and control groups and were identified using mass spectrometry. This process led to the identification of 18 pancreatic immunoreactive antigens such as laminin, superoxide dismutase, ATP synthase, Rho GDP-dissociation inhibitor II, septin, glyceraldehyde 3-phosphate-dehydrogenase, phosphoglycerate mutase B, tubulin β8 channel and prohibit in. In the present study, we identified 18 immunoreactive proteins in PDAC. While the identified proteins were critically involved in PDAC pathogenesis, further investigation in a large scale population will determine the applicability of these potential biomarkers for the early diagnosis or treatment of the disease.

show abstract

Expression of Elongation Factor (EF)-Tu Is Correlated with Prognosis of Gastric Adenocarcinomas

Cited by 11 publications

References 29 publications

Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting

Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting

Expression and clinicopathologic significance of TUFM and p53 for the normal–adenoma–carcinoma sequence in colorectal epithelia

Identification of antibody reactive proteins in pancreatic cancer using 2D immunoblotting and mass spectrometry

Contact Info

Product

Resources

About